Lunai Bioworks Inc.
LNAIHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lunai Bioworks Inc. focuses on Biotechnology services and products. Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. The $1.3M market capitalization puts LNAI squarely in micro-cap range for its industry. It operates through two segments, RENB and BioSymetrics.
Market Cap
$1.3M
Beta
0.35
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.67
EPS (Fwd)
—
ROE
—
ROA
-54.1%
Cash
$1.7M
Total Debt
$1.5M
Free CF
-$5.7M
52W Change
-96.6%
Annual Financials
Cash vs Debt
Where LNAI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LNAI finished 81.20% below its 150-day moving average ($2.50) and 85.31% below its 200-day moving average ($3.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNAI overbought or oversold?
At the October 20, 2026 close, LNAI's RSI(14) was 8.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.7M in cash comfortably exceeding the $1.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
LNAI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Lunai Bioworks Inc.'s trajectory.